Amerikanische Gesellschaft für Hirudotherapie

Heparin-induced thrombocytopenia: a general review

Review published in J Infus Nurs (2007)

Zuletzt aktualisiert: June 18, 2026Geprüft von: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Narrative reviewArzneimittelentwicklungKlinische StudienSwanson JM · Journal of infusion nursing, 2007

Abstract

Unfractionated heparin is widely used for numerous clinical situations. A well-known adverse effect of heparin exposure is thrombocytopenia. Heparin-induced thrombocytopenia is a clinicopathologic syndrome that can be associated with severe complications and significant mortality. The pathophysiology of heparin-induced thrombocytopenia includes an immune-mediated reaction to heparin that activates platelets and results in an acquired hypercoagulability. Diagnosis of heparin-induced thrombocytopenia should incorporate clinical signs and symptoms and laboratory testing for heparin-induced thrombocytopenia antibodies. Therapy should include discontinuation of heparin, initiation of a direct thrombin inhibitor, and eventually therapy with warfarin (only after the platelet count is at least 100 x 10(9)/L).

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleReview
Indexed MeSH termsAnticoagulantsArginineDrug MonitoringFactor Xa InhibitorsFondaparinuxHeparinHirudinsHumansNursing AssessmentPeptide FragmentsPipecolic AcidsPlatelet Activation

Zusammenfassung

Nursing-focused review of HIT diagnosis and management including DTI therapy initiation and warfarin transition once platelet count exceeds 100x10^9/L.

Warum dies für die Hirudotherapie relevant ist

This general review covers heparin-induced thrombocytopenia as a clinicopathologic syndrome, describing its immune-mediated pathophysiology, the importance of combining clinical assessment with laboratory antibody testing for diagnosis, and a treatment algorithm of heparin discontinuation, initiation of a direct thrombin inhibitor, and eventual warfarin transition only after platelet recovery to at least 100 × 10⁹/L. The abstract refers generically to direct thrombin inhibitors without naming lepirudin, hirudin, or any specific agent, and does not mention leeches or the leech secretome. Therefore, no specific relevance to hirudotherapy can be established from the abstract text, and the connection is at most indirect. The abstract provides no primary data and no hirudin-specific pharmacology or outcomes.

Zitation

Heparin-induced thrombocytopenia: a general review.

Swanson JM · Journal of infusion nursing, 2007

Verwandter klinischer Kontext

Erfahren Sie, wie diese Forschung mit der klinischen Praxis verknüpft ist

Zur ASH-Bibliothek hinzugefügt: May 27, 2026 · Letzte Aktualisierung der Website: June 18, 2026

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.